Preparation and characterization of a glycyrrhizic acid-based drug delivery system for allergen-specific immunotherapy

Standard

Preparation and characterization of a glycyrrhizic acid-based drug delivery system for allergen-specific immunotherapy. / Pashkina, Ekaterina; Evseenko, Veronika; Dumchenko, Natalya et al.

In: Nanomaterials, Vol. 12, No. 1, 148, 01.01.2022.

Research output: Contribution to journal › Article › peer-review

Harvard

Pashkina, E, Evseenko, V, Dumchenko, N, Zelikman, M, Aktanova, A, Bykova, M, Khvostov, M, Dushkin, A & Kozlov, V 2022, 'Preparation and characterization of a glycyrrhizic acid-based drug delivery system for allergen-specific immunotherapy', Nanomaterials, vol. 12, no. 1, 148. https://doi.org/10.3390/nano12010148

APA

Pashkina, E., Evseenko, V., Dumchenko, N., Zelikman, M., Aktanova, A., Bykova, M., Khvostov, M., Dushkin, A., & Kozlov, V. (2022). Preparation and characterization of a glycyrrhizic acid-based drug delivery system for allergen-specific immunotherapy. Nanomaterials, 12(1), [148]. https://doi.org/10.3390/nano12010148

Vancouver

Pashkina E, Evseenko V, Dumchenko N, Zelikman M, Aktanova A, Bykova M et al. Preparation and characterization of a glycyrrhizic acid-based drug delivery system for allergen-specific immunotherapy. Nanomaterials. 2022 Jan 1;12(1):148. doi: 10.3390/nano12010148

Author

Pashkina, Ekaterina ; Evseenko, Veronika ; Dumchenko, Natalya et al. / Preparation and characterization of a glycyrrhizic acid-based drug delivery system for allergen-specific immunotherapy. In: Nanomaterials. 2022 ; Vol. 12, No. 1.

BibTeX

@article{ee27262f62b34881852c9c198cef3989,

title = "Preparation and characterization of a glycyrrhizic acid-based drug delivery system for allergen-specific immunotherapy",

abstract = "The most effective method of treating allergic diseases, aimed not at relieving symptoms, but at eliminating the cause of the disease, is allergen-specific immunotherapy (AIT). To reduce the risk of side effects and improve the delivery of allergens to the mucosa, various delivery systems, such as liposomes, dendrimers, nanoparticles, etc., can be used. To date, there are data on the creation of delivery systems based on glycyrrhizic acid (GA) and its derivatives, but such a delivery system has not been used for allergen-specific therapy until now. It is also known that GA has an anti-inflammatory effect, shifts the balance towards Th1, and increases the number of Treg cells, meaning that it could potentially enhance the anti-allergic effect of AIT and reduce the risk of unwanted side effects. Thus, the study of the immunomodulatory effect of the supramolecular complexes (micelles) of GA with extracts of allergens holds promise for the development of new drugs for AIT.",

keywords = "Allergen-specific immunotherapy, Drug delivery, Glycyrrhizic acid, House dust mite",

author = "Ekaterina Pashkina and Veronika Evseenko and Natalya Dumchenko and Maxim Zelikman and Alina Aktanova and Maria Bykova and Mikhail Khvostov and Aleksandr Dushkin and Vladimir Kozlov",

note = "Funding Information: The reported study was funded by RFBR, project number 20-315-70039. Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = jan,

day = "1",

doi = "10.3390/nano12010148",

language = "English",

volume = "12",

journal = "Nanomaterials",

issn = "2079-4991",

publisher = "MDPI AG",

number = "1",

}

RIS

TY - JOUR

T1 - Preparation and characterization of a glycyrrhizic acid-based drug delivery system for allergen-specific immunotherapy

AU - Pashkina, Ekaterina

AU - Evseenko, Veronika

AU - Dumchenko, Natalya

AU - Zelikman, Maxim

AU - Aktanova, Alina

AU - Bykova, Maria

AU - Khvostov, Mikhail

AU - Dushkin, Aleksandr

AU - Kozlov, Vladimir

PY - 2022/1/1

Y1 - 2022/1/1

N2 - The most effective method of treating allergic diseases, aimed not at relieving symptoms, but at eliminating the cause of the disease, is allergen-specific immunotherapy (AIT). To reduce the risk of side effects and improve the delivery of allergens to the mucosa, various delivery systems, such as liposomes, dendrimers, nanoparticles, etc., can be used. To date, there are data on the creation of delivery systems based on glycyrrhizic acid (GA) and its derivatives, but such a delivery system has not been used for allergen-specific therapy until now. It is also known that GA has an anti-inflammatory effect, shifts the balance towards Th1, and increases the number of Treg cells, meaning that it could potentially enhance the anti-allergic effect of AIT and reduce the risk of unwanted side effects. Thus, the study of the immunomodulatory effect of the supramolecular complexes (micelles) of GA with extracts of allergens holds promise for the development of new drugs for AIT.

AB - The most effective method of treating allergic diseases, aimed not at relieving symptoms, but at eliminating the cause of the disease, is allergen-specific immunotherapy (AIT). To reduce the risk of side effects and improve the delivery of allergens to the mucosa, various delivery systems, such as liposomes, dendrimers, nanoparticles, etc., can be used. To date, there are data on the creation of delivery systems based on glycyrrhizic acid (GA) and its derivatives, but such a delivery system has not been used for allergen-specific therapy until now. It is also known that GA has an anti-inflammatory effect, shifts the balance towards Th1, and increases the number of Treg cells, meaning that it could potentially enhance the anti-allergic effect of AIT and reduce the risk of unwanted side effects. Thus, the study of the immunomodulatory effect of the supramolecular complexes (micelles) of GA with extracts of allergens holds promise for the development of new drugs for AIT.

KW - Allergen-specific immunotherapy

KW - Drug delivery

KW - Glycyrrhizic acid

KW - House dust mite

UR - http://www.scopus.com/inward/record.url?scp=85122194932&partnerID=8YFLogxK

U2 - 10.3390/nano12010148

DO - 10.3390/nano12010148

M3 - Article

C2 - 35010098

AN - SCOPUS:85122194932

VL - 12

JO - Nanomaterials

JF - Nanomaterials

SN - 2079-4991

IS - 1

M1 - 148

ER -

ID: 35243550